Research Article Volume 01, Issue No. 02. 2025

THE MEDICAL JOURNAL OF PSYCHIATRY AND NEUROSURGERY



Bright Light Therapy for Nonseasonal Depressive Disorders

[1] Yohanes, [1] Mutiara

[1] Faculty of Medicine, Maranatha Christian University, Bandung City, West Java, Indonesia

Correspondence : dr.yohanes9847372@gmail.com

Article History :

Received date : 2024/07/19
Revised date : 2024/08/22
Accepted date : 2024/09/08
Published date : 2025/10/20

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: Bright light therapy (BLT) has emerged as a promising treatment for nonseasonal depressive disorders, with multiple studies exploring its efficacy and underlying mechanisms. **Literature Review:** A systematic review and meta-analysis (Perera et al., 2016) further elucidates the potential mechanisms by which light therapy alleviates depressive symptoms, particularly in individuals with circadian rhythm disturbances. However, the limited number of trials meeting strict inclusion criteria raises concerns about the robustness of the findings, emphasizing the need for more comprehensive research. The necessity of validating the efficacy of adjunct light therapy before its integration into treatment plans for major depressive disorder (MDD) is underscored by (Müller et al., 2018), who calls for investigations into the side effects of combined treatments. This concern is echoed in (Walsh, 2018), who contrasts light therapy with selective serotonin reuptake inhibitors (SSRIs), highlighting the complexities of establishing a standardized treatment regimen for non-seasonal depression. Historical perspectives on light therapy's applications in psychiatric disorders are provided by (Kaladchibachi & Fernandez, 2018), noting its success in treating seasonal affective disorder (SAD) and its potential for nonseasonal depression. Nonetheless, recent meta-analyses have raised questions about the statistical significance of therapeutic effects, indicating the need for rigorous investigations. **Conclusion:** In conclusion, the literature collectively underscores the potential of bright light therapy as a viable treatment for nonseasonal depressive disorders, while also highlighting critical gaps in research that necessitate further exploration. Addressing these gaps will be essential for optimizing the clinical application of light therapy and enhancing its integration into treatment protocols for mood disorders.

Keyword: Bright Light Therapy, Nonseasonal Depressive Disorders

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The exploration of bright light therapy (BLT) as a treatment for nonseasonal depressive disorders has garnered increasing attention in recent years, with a growing body of literature examining its efficacy, mechanisms, and implications for clinical practice. The foundational work by (Roecklein et al., 2012) highlights the cognitive and behavioral predictors influencing individuals' decisions to engage in light therapy, suggesting that self-efficacy and social support play crucial roles in treatment uptake. This insight underscores the importance of addressing psychological factors in promoting adherence to light therapy, particularly in the context of mood disorders.

Building on this premise, (Perera et al., 2016) conducted a systematic review and meta-analysis that focused on the application of light therapy for non-seasonal depression. They elucidate the potential mechanisms through which light therapy may alleviate depressive symptoms, particularly in individuals exhibiting circadian rhythm disturbances. However, their findings reveal a significant gap in the literature, as only two trials met their strict inclusion criteria, highlighting the need for more comprehensive research to assess the efficacy of light therapy in non-seasonal depressive disorders.

(Müller et al., 2018) further emphasize the necessity of verifying the efficacy of adjunct light therapy before its integration into treatment plans for major depressive disorder (MDD). Their call for additional studies to investigate the side effects of combined treatments reflects the ongoing concerns regarding the safety and tolerability of light therapy in clinical settings.

In the same year, (Walsh, 2018) explored the therapeutic potential of light therapy within primary care, contrasting it with the commonly prescribed selective serotonin reuptake inhibitors (SSRIs). She notes the multifactorial nature of non-seasonal depression, which complicates the establishment of a standardized light-

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

driven treatment regimen. Walsh's analysis points to the promise of light therapy as an adjunctive treatment with minimal side effects, contrasting with the adverse effects often associated with SSRIs.

(Kaladchibachi & Fernandez, 2018) contribute to the discourse by examining the historical context and evolving understanding of light therapy in psychiatric disorders. They highlight the success of bright light in treating seasonal affective disorder (SAD) and its potential applicability to nonseasonal forms of depression. However, they also caution that recent meta-analyses have raised questions about the statistical significance of the therapeutic effects of light exposure, calling for further rigorous investigations.

Continuing this line of inquiry, (Maruani et al., 2019) present evidence supporting the efficacy of bright light therapy in non-seasonal major depressive disorder, particularly when used in conjunction with pharmacological treatments like citalopram. They note that while light therapy can enhance the antidepressant effects of medications, there remains a lack of sustained benefits following treatment discontinuation, indicating the need for ongoing research into the long-term efficacy of light therapy.

In a more recent study, (Maruani & A. Geoffroy, 2022) delve into the historical significance and modern applications of light therapy for mood regulation. They advocate for the recognition of light therapy as a viable treatment option for non-seasonal depression, emphasizing the importance of understanding the underlying neural mechanisms to tailor treatment approaches effectively.

Finally, (Zhou et al., 2022) provide a systematic review and meta-analysis that consolidates findings on the effectiveness of high circadian stimulus lighting therapy for depression. Their work underscores the importance of circadian regulation in depressive disorders and positions BLT as a recommended therapeutic strategy within clinical guidelines for non-seasonal depression. They also highlight the need for a refined model of human circadian phototransduction to better understand the relationship between light exposure and therapeutic outcomes.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Collectively, these articles reflect a growing recognition of bright light therapy's potential as a treatment modality for nonseasonal depressive disorders, while also identifying critical gaps in the literature that warrant further exploration to optimize its application in clinical practice.

LITERATURE REVIEW

The article "Cognitive and behavioral predictors of light therapy use" by (Roecklein et al., 2012) provides a critical examination of the factors influencing individuals' decisions to engage in light therapy (LT) for nonseasonal depressive disorders. The authors highlight a paradox wherein, despite the mild side effects associated with LT and the credible rationale linking light exposure to mood enhancement, many individuals refrain from utilizing this therapeutic approach.

A central theme of the article is the role of cognitive and behavioral factors, particularly self-efficacy and social support, in the decision-making process regarding LT. The authors argue that these psychological constructs are pivotal in shaping individuals' perceptions of their ability to manage their depressive symptoms and the effectiveness of the treatment itself. This insight is particularly valuable as it suggests that interventions aimed at enhancing self-efficacy could potentially increase the uptake of LT among those who might benefit from it.

Furthermore, the article posits that social support plays a significant role in the decision to use LT. The presence of supportive relationships may bolster an individual's confidence in pursuing treatment options, thereby influencing their overall engagement with LT. This aspect underscores the importance of considering the social context when evaluating treatment adherence and efficacy in mood disorders.

(Roecklein et al., 2012) implies that cognitive-behavioral strategies could be developed to address the barriers to LT use. By focusing on modifying thoughts and appraisals related to both symptoms and treatment, healthcare providers can enhance the likelihood of patients opting for LT, potentially leading to improved outcomes in managing nonseasonal depressive disorders.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The systematic review and meta-analysis conducted by (Perera et al., 2016) provides a comprehensive examination of the use of light therapy for individuals suffering from non-seasonal depressive disorders. The authors present a well-defined rationale for the application of light therapy, particularly highlighting the atypical symptoms often associated with non-seasonal depression, such as irregular sleep–wake patterns and diurnal mood swings. This is significant, as these symptoms are indicative of underlying circadian rhythm disruptions, suggesting that light therapy may offer a viable intervention by targeting these abnormalities.

The review's methodology is noteworthy, as it adheres to strict inclusion criteria, focusing exclusively on randomized controlled trials (RCTs) that compare light therapy to inactive placebo or control groups. However, this stringent approach also resulted in the inclusion of only two trials specifically addressing non-seasonal depression. This limitation raises concerns regarding the robustness of the conclusions drawn about the efficacy of light therapy, as the small sample size may not adequately represent the broader population of individuals with non-seasonal depressive disorders. The authors acknowledge this gap, noting the need for further research to substantiate the findings and to explore the potential efficacy of light therapy in a more diverse cohort.

(Perera et al., 2016) also delve into the potential mechanisms through which light therapy may exert its effects. The activation of the suprachiasmatic nucleus (SCN) via light exposure is posited as a critical pathway, influencing mood, sleep, circadian rhythms, and the hypothalamic–pituitary–adrenal (HPA) axis activity. Despite this theoretical framework, the authors candidly admit that the precise mechanisms remain elusive, indicating a need for future studies to clarify how light therapy interacts with these biological systems.

Additionally, the review seeks to identify potential covariates that may modify the efficacy of light therapy and to summarize any adverse effects associated with treatment. This aspect is crucial, as understanding the variability in response to light therapy could lead to more personalized treatment approaches for individuals with non-seasonal depression.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article "Side effects of adjunct light therapy in patients with major depression" by (Müller et al., 2018) presents a critical examination of the implications of incorporating light therapy as an adjunct treatment for individuals suffering from major depressive disorder (MDD). The authors emphasize the necessity of validating the efficacy of light therapy before its routine application in non-seasonal MDD treatment protocols.

One of the primary contributions of this article is its focus on the potential side effects associated with the combination of light therapy and other treatment modalities. (Müller et al., 2018) argue that while light therapy shows promise, it is essential to conduct further research to elucidate the safety and tolerability of this approach, particularly when used alongside pharmacological treatments. The authors highlight that the current literature lacks comprehensive studies that systematically investigate these side effects, which could impede the broader acceptance and application of light therapy in clinical settings.

The article also underscores the importance of individualized treatment plans, suggesting that not all patients may respond similarly to light therapy. This perspective encourages clinicians to consider patient-specific factors, such as the severity of depression and the presence of comorbid conditions, when determining the appropriateness of light therapy as an adjunct treatment. Furthermore, the authors call for rigorous clinical trials to establish standardized protocols and to better understand the mechanisms through which light therapy may exert its effects on mood regulation.

In "Light Therapy: Therapeutic Potential for the Management of Depression in Primary Care," (Walsh, 2018) explores the application of light treatment in addressing non-seasonal depressive disorders, a topic of increasing relevance in contemporary mental health care. The article critically evaluates the complexities surrounding non-seasonal depression, emphasizing its multifactorial nature, which complicates the establishment of a standardized light-driven treatment regimen. This acknowledgment of the disorder's variability is crucial, as it highlights the challenges clinicians face when considering light therapy as a viable option.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

(Walsh, 2018) notes that while pharmacological interventions, particularly selective serotonin reuptake inhibitors (SSRIs), are commonly employed in treating non-seasonal depression, they are accompanied by significant adverse effects such as gastrointestinal disturbances, weight fluctuations, sexual dysfunction, and sleep issues. These side effects can deter patients from adhering to their prescribed treatment plans, thereby underscoring the need for alternative therapeutic strategies. The slow onset of SSRIs in producing a noticeable therapeutic response further complicates their effectiveness, particularly in patients seeking immediate relief from depressive symptoms.

The article delves into the emerging understanding of the relationship between circadian rhythms and affective disorders, suggesting that disruptions in circadian functioning could be a contributing factor to the manifestation of these conditions. This perspective opens the door for light therapy as a potential adjunctive treatment, given its non-invasive nature and minimal side effects. (Walsh, 2018)'s assertion that light therapy shows promise in this context is supported by the growing body of research indicating that light exposure can positively influence mood and circadian regulation.

However, the article also emphasizes the necessity for further clinical investigation to substantiate the efficacy of light therapy in treating non-seasonal depression. This call for additional research is critical, as it reflects the current gaps in the literature regarding standardized treatment protocols and the specific mechanisms by which light therapy may exert its effects on mood regulation.

The article "Precision Light for the Treatment of Psychiatric Disorders" by (Kaladchibachi & Fernandez, 2018) provides a comprehensive overview of the application of bright light therapy in the context of various mood disorders, including nonseasonal depressive disorders such as bipolar disorder and major depressive disorder. The authors effectively argue that mood disorders possess circadian underpinnings, suggesting that the timed delivery of light may serve as a viable treatment or adjunct therapy.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article highlights significant findings from previous studies that demonstrate the potential of bright light exposure to alleviate depressive symptoms. Notably, the authors reference successful outcomes from the 1990s, where scheduled morning exposure to high-intensity light (2500–10,000 lux) over a two-week period resulted in substantial reductions in behavioral ratings of depression. The reported remission rates of 30–60% among participants represent a noteworthy achievement, particularly when compared to traditional antidepressant medications, which often exhibit lower efficacy in clinical trials.

However, the authors also present a critical perspective on the body of research surrounding bright light therapy. They note that subsequent meta-analyses have yielded mixed results regarding its effectiveness for both seasonal and nonseasonal depression. This ambivalence raises questions about the robustness of the existing literature, suggesting that many studies may suffer from flawed experimental designs. The authors caution that while some randomized and double-blind clinical trials continue to support the utility of light exposure for symptom relief, the overall evidence base must be interpreted with caution.

The article "Bright Light as a Personalized Precision Treatment of Mood Disorders" by (Maruani et al., 2019) provides a comprehensive examination of bright light therapy (BLT) as a treatment option for non-seasonal depressive disorders. The authors present a compelling case for the efficacy of BLT, detailing its rapid action and effectiveness, particularly when used in conjunction with pharmacological treatments such as citalopram. This combination appears to enhance the therapeutic outcomes for patients, which is a significant finding in the context of managing major depressive disorder (MDD).

The clinical trials referenced in the article highlight the potential of bright light therapy to expedite the antidepressant effects, especially among elderly patients suffering from MDD. This demographic is particularly vulnerable to the debilitating effects of depression, and the findings suggest that BLT could be a valuable tool in their treatment arsenal. The meta-analyses cited further reinforce the notion that

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

BLT is not only effective but also presents a viable option specifically for older patients with non-seasonal depression.

However, the article does not shy away from discussing the limitations of bright light therapy. Notably, the authors point out that some studies indicate the benefits of the treatment may diminish after discontinuation, raising questions about the long-term sustainability of its effects. This aspect is crucial for practitioners considering BLT as a treatment modality, as it suggests that ongoing management may be necessary to maintain therapeutic benefits.

The article "Multi-Level Processes and Retina–Brain Pathways of Photic Regulation of Mood" by (Maruani & A. Geoffroy, 2022) provides an in-depth exploration of light therapy (LT) as a treatment for nonseasonal depressive disorders, highlighting its historical context and recent advancements in neuroscientific understanding. The authors trace the evolution of LT from its ancient origins to its modern resurgence, particularly emphasizing pivotal studies from 1979 and 1980 that established its antidepressant effects.

A significant contribution of this article is its assertion that LT is not solely effective for seasonal affective disorder (SAD), but also shows promise for nonseasonal depression. The authors cite various randomized controlled trials that demonstrate LT's efficacy compared to placebo in both unipolar and bipolar depression, reinforcing its potential as a viable treatment option across different depressive subtypes. This finding is crucial, as it expands the clinical applications of LT beyond seasonal patterns, advocating for its consideration as a first-line treatment.

Moreover, the article discusses the potential of LT to be utilized as a monotherapy or in conjunction with antidepressants, suggesting that it can enhance the therapeutic response in patients who do not adequately respond to traditional pharmacological treatments. The recommendation for a first-line combination treatment underscores the need for personalized approaches to depression management, which is a noteworthy emphasis in contemporary psychiatric practice.

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The authors also delve into the neurobiological mechanisms underlying the mood-regulating effects of light, particularly through the discovery of melanopsin. This advancement provides a clearer understanding of how light influences mood regulation, which is essential for tailoring LT to individual patient needs. The identification of neural pathways involved in photic regulation marks a significant step toward developing more effective chronotherapeutics in mood disorders.

The article "High circadian stimulus lighting therapy for depression: Meta-analysis of clinical trials" by (Zhou et al., 2022) offers a comprehensive examination of Bright Light Therapy (BLT) as an effective intervention for non-seasonal depressive disorders (NSD). The authors present a systematic review and meta-analysis that underscores the therapeutic potential of BLT, particularly in relation to circadian rhythm regulation and its implications for depression treatment.

The article emphasizes that BLT has been validated as a safe and effective treatment modality for NSD, demonstrating significant alleviation of depressive symptoms with light exposure ranging from 0.5 to 6 hours per day. The standard treatment spectrum for NSD has predominantly been white light, with recommended intensities of 10,000 lux. This aligns with existing clinical guidelines, reinforcing the utility of high-intensity lighting in therapeutic contexts. Notably, the authors also explore the potential benefits of blue and green light, suggesting that these wavelengths may provide positive therapeutic effects, thereby broadening the scope of light therapy applications.

A critical aspect of the article is its exploration of the relationship between circadian rhythm disturbances and depressive disorders. The authors discuss how disruptions in circadian rhythms, evidenced by delayed melatonin secretion, are prevalent in both seasonal affective disorder (SAD) and NSD. This connection highlights the importance of melatonin regulation through light exposure, which may serve as a fundamental mechanism underlying the effectiveness of BLT. The authors propose that a refined model of human circadian phototransduction is necessary for quantifying light as a stimulus, advocating for the circadian stimulus (CS) model. This model takes into account the spectral sensitivity of retinal photoreceptor cells

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

and their role in signaling the biological clock, thus offering a more nuanced understanding of how light can influence mood and behavior.

The systematic review and meta-analysis presented in the article provide robust evidence for the efficacy of BLT, particularly through the lens of the CS model. By correlating CS values with therapeutic outcomes, the authors contribute valuable insights into the quantification of lighting doses for clinical applications. This methodological approach not only enhances the scientific rigor of the findings but also establishes a framework for future research in this domain.

However, the article does highlight some limitations, particularly in the Cochrane review's finding that no significant difference was observed between bright light (>2500 lux) and control groups (2500 lux maximum). This raises questions about the threshold levels of light exposure required for optimal therapeutic effects, suggesting that further investigation is necessary to delineate effective lighting parameters.

CONCLUSION

Bright light therapy (BLT) has emerged as a promising treatment for nonseasonal depressive disorders, with multiple studies exploring its efficacy and underlying mechanisms. The literature indicates that cognitive and behavioral factors, such as self-efficacy and social support, significantly influence individuals' decisions to engage in light therapy (Roecklein et al., 2012). This highlights the need for addressing psychological constructs to enhance treatment adherence.

A systematic review and meta-analysis (Perera et al., 2016) further elucidates the potential mechanisms by which light therapy alleviates depressive symptoms, particularly in individuals with circadian rhythm disturbances. However, the limited number of trials meeting strict inclusion criteria raises concerns about the robustness of the findings, emphasizing the need for more comprehensive research.

The necessity of validating the efficacy of adjunct light therapy before its integration into treatment plans for major depressive disorder (MDD) is

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

underscored by (Müller et al., 2018), who calls for investigations into the side effects of combined treatments. This concern is echoed in (Walsh, 2018), who contrasts light therapy with selective serotonin reuptake inhibitors (SSRIs), highlighting the complexities of establishing a standardized treatment regimen for non-seasonal depression.

Historical perspectives on light therapy's applications in psychiatric disorders are provided by (Kaladchibachi & Fernandez, 2018), noting its success in treating seasonal affective disorder (SAD) and its potential for nonseasonal depression. Nonetheless, recent meta-analyses have raised questions about the statistical significance of therapeutic effects, indicating the need for rigorous investigations.

Research by (Maruani et al., 2019) supports the efficacy of bright light therapy in conjunction with pharmacological treatments, although concerns regarding the sustainability of benefits post-treatment discontinuation remain. Meanwhile, (Maruani & A. Geoffroy, 2022) emphasizes the importance of understanding the neural mechanisms underlying light therapy to tailor treatment approaches effectively.

Finally, the systematic review and meta-analysis by (Zhou et al., 2022) consolidates findings on high circadian stimulus lighting therapy, advocating for its inclusion in clinical guidelines for non-seasonal depression while recognizing the need for a refined understanding of circadian phototransduction.

In conclusion, the literature collectively underscores the potential of bright light therapy as a viable treatment for nonseasonal depressive disorders, while also highlighting critical gaps in research that necessitate further exploration. Addressing these gaps will be essential for optimizing the clinical application of light therapy and enhancing its integration into treatment protocols for mood disorders.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved

- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Roecklein, K. A., Schumacher, J. A., Miller, M. A., & Ernecoff, N. C., 2012. Cognitive and behavioral predictors of light therapy use. [PDF]
2. Perera, S., Eisen, R., Bhatt, M., Bhatnagar, N., de Souza, R., Thabane, L., & Samaan, Z., 2016. Light therapy for non-seasonal depression: systematic review and meta-analysis. ncbi.nlm.nih.gov
3. Müller, M., Seifritz, E., Hatzinger, M., Hemmeter, U., & Holsboer-Trachsler, E., 2018. Side effects of adjunct light therapy in patients with major depression. [PDF]
4. Walsh, J., 2018. Light Therapy: Therapeutic Potential for the Management of Depression in Primary Care. [PDF]
5. Kaladchibachi, S. & Fernandez, F., 2018. Precision Light for the Treatment of Psychiatric Disorders. ncbi.nlm.nih.gov
6. Maruani, J., Maruani, J., Maruani, J., Maruani, J., Alexis Geoffroy, P., Alexis Geoffroy, P., Alexis Geoffroy, P., & Alexis Geoffroy, P., 2019. Bright Light as a Personalized Precision Treatment of Mood Disorders. [PDF]
7. Maruani, J. & A. Geoffroy, P., 2022. Multi-Level Processes and Retina–Brain Pathways of Photic Regulation of Mood. ncbi.nlm.nih.gov
8. Zhou, L., Hou, D., Wang, Y., Zhou, S., & Lin, Y., 2022. High circadian stimulus lighting therapy for depression: Meta-analysis of clinical trials. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Psychiatry And Neurosurgery
Copyright © International Medical Journal Corp. Ltd. All rights reserved